<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02777567</url>
  </required_header>
  <id_info>
    <org_study_id>D5160R00009</org_study_id>
    <nct_id>NCT02777567</nct_id>
  </id_info>
  <brief_title>KOREA Study (Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy)</brief_title>
  <acronym>KOREA</acronym>
  <official_title>Open Label, Multicenter, Real World Treatment Study of Single Agent Tagrisso for Patients With Advanced/Metastatic Epidermal Growth Factor Receptor (EGFR) T790M Mutation-Positive Non-Small Cell Lung Cancer (NSCLC), Who Have Progressed on or After EGFR Tyrosine Kinase Receptor (TKI) Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to assess the safety and efficacy of single agent Tagrisso
      (Osimertinib, hereinafter &quot;the study drug&quot;) in a real world setting in adult patients with
      advanced or metastatic, epidermal growth factor receptor (EGFR) T790M mutation-positive
      Non-Small Cell Lung Cancer (NSCLC), Who Have Progressed on or after EGFR tyrosine kinase
      receptor (TKI) therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 29, 2016</start_date>
  <completion_date type="Anticipated">September 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion (%) of patients with adverse events (AEs), serious adverse events (SAEs) and AEs of special interest (AESI)</measure>
    <time_frame>up to one year</time_frame>
    <description>Proportion (%) of patients with adverse events (AEs), serious adverse events (SAEs) and AEs of special interest (AESI)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of (S)AEs</measure>
    <time_frame>up to one year</time_frame>
    <description>Severity of (S)AEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR (Objective response rate), if available</measure>
    <time_frame>up to one year</time_frame>
    <description>ORR (Objective response rate), if available</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS (Progression free survival), if available</measure>
    <time_frame>up to one year</time_frame>
    <description>PFS (Progression free survival), if available</description>
  </secondary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with locally advanced or metastatic, EGFR T790M mutation-positive NSCLC, who have
        progressed on or after EGFR tyrosine kinase receptor (TKI) therapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Eligible for, or on active study drug treatment according to the approved label;
             patients with locally advanced or metastatic, EGFR T790M mutation-positive NSCLC, who
             have progressed on or after EGFR tyrosine kinase receptor (TKI) therapy

          -  2. Provision of signed and dated written informed consent by the patient or legally
             acceptable representative

        Exclusion Criteria:

          -  1. History of hypersensitivity to excipients of the study drug or to drugs with a
             similar chemical structure or class to the study drug

          -  2. Pregnancy and/or breast feeding

          -  3. Current participation in any interventional trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>South Korea</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2016</study_first_submitted>
  <study_first_submitted_qc>May 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2016</study_first_posted>
  <last_update_submitted>May 10, 2018</last_update_submitted>
  <last_update_submitted_qc>May 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

